El nacimiento muy prematuro (VPT) o con muy bajo peso al nacer (VLBW) constituye un contexto de riesgo biopsicosocial para la salud mental parental y el desarrollo infantil. El proyecto se articula en tres estudios. El primer estudio examina la salud mental parental temprana y el vínculo postnatal durante el ingreso en la unidad neonatal, comparando progenitores de bebés VPT/VLBW con progenitores de bebés nacidos a término. El segundo estudio describe las trayectorias del neurodesarrollo entre los 12, 24 y 36 meses y analiza la relación prospectiva entre el neurodesarrollo temprano y los problemas emocionales y conductuales posteriores. El tercer estudio analiza predictores biomédicos y psicosociales del neurodesarrollo cognitivo, lingüístico y motor durante los tres primeros años de vida. En conjunto, estos estudios contribuyen a una comprensión biopsicosocial de las trayectorias del desarrollo en niños nacidos VPT/VLBW, integrando factores biomédicos, psicológicos, relacionales y contextuales.
Gene therapy is a promising therapeutic approach based on the delivery of genetic material into target cells to modulate or restore cellular function. Although viral vectors remain the most widely used delivery system due to their high transfection efficiency, concerns related to immunogenicity, safety, limited cargo capacity, and manufacturing complexity have driven increasing interest in non-viral alternatives. In recent years, the development of non-viral vectors has expanded considerably due to their versatility, scalability, and modifiable physicochemical properties.
This seminar focuses on the development of PAH-PEG-OA cationic polymers as non-viral gene delivery systems. Their application is explored in different therapeutic contexts, particularly osteoarthritis and CAR-T cell therapy. In osteoarthritis, these nanoparticles represent a promising strategy for modulating inflammation and pain through siRNA delivery. In parallel, the use of polymer- and lipid-based vectors in CAR-T therapy is discussed as a potential approach to simplify and improve current ex vivo genetic engineering processes while reducing dependence on viral systems.
Overall, this work highlights the growing relevance of rationally designed non-viral vectors as adaptable platforms for next-generation gene therapies and biomedical applications.